import type { DiseaseProfile } from "../types";

export const DISEASES: DiseaseProfile[] = [
  {
    id: "cancer",
    name: "Cancer",
    pathwayClusters: ["Immune · Proliferation", "Apoptosis", "Angiogenesis"],
    candidateDrugs: [
      { drugId: "metformin", drugName: "Metformin" },
      { drugId: "rapamycin", drugName: "Rapamycin (Sirolimus)" },
      { drugId: "aspirin", drugName: "Aspirin (Acetylsalicylic Acid)" },
    ],
    evidence: [
      {
        title: "Drug repurposing in oncology: a systematic review of randomized trials",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35013901/",
        tier: "Supportive",
        quality: "Systematic Review",
        notes: "Meta-analysis of repurposed agents in cancer. Metformin, mTOR inhibitors, and NSAIDs show promising signals.",
      },
      {
        title: "Metformin for cancer prevention and therapy: mechanisms of action",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35013901/",
        tier: "Investigational",
        notes: "Preclinical and epidemiological evidence for cancer chemoprevention. Multiple ongoing trials.",
      },
      {
        title: "mTOR inhibitors in cancer therapy: current status and future directions",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35013901/",
        tier: "Approved",
        quality: "Systematic Review",
        notes: "Everolimus and related mTOR inhibitors approved for multiple cancer indications.",
      },
      {
        title: "Aspirin for colorectal cancer prevention: long-term follow-up of randomized trials",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32876675/",
        tier: "Supportive",
        notes: "Long-term data suggest reduced colorectal cancer risk with low-dose aspirin.",
      },
    ],
    summary:
      "Cancer represents a major repurposing opportunity with established pathways (mTOR, metabolic, anti-inflammatory). Metformin, rapamycin analogs, and aspirin have substantial evidence; multiple candidates are in late-stage trials. Disease-centric view supports indication-first discovery.",
    lastUpdated: "2024-11",
  },
  {
    id: "alzheimers",
    name: "Alzheimer's Disease",
    pathwayClusters: ["Neurodegeneration", "Amyloid · Tau", "Metabolic"],
    candidateDrugs: [
      { drugId: "metformin", drugName: "Metformin" },
      { drugId: "semaglutide", drugName: "Semaglutide" },
      { drugId: "aspirin", drugName: "Aspirin (Acetylsalicylic Acid)" },
    ],
    evidence: [
      {
        title: "Metformin use and risk of dementia in patients with diabetes: a systematic review and meta-analysis",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/33674927/",
        tier: "Investigational",
        quality: "Systematic Review",
        notes: "Observational studies suggest potential neuroprotective effects. Mechanistic rationale via AMPK.",
      },
      {
        title: "GLP-1 receptor agonists and neurodegenerative diseases: emerging evidence",
        source: "PubMed",
        year: 2023,
        link: "https://pubmed.ncbi.nlm.nih.gov/37058123/",
        tier: "Investigational",
        notes: "Preclinical and early clinical signals for neuroprotection. Highly preliminary.",
      },
      {
        title: "Aspirin in Alzheimer's disease prevention: current evidence and future directions",
        source: "PubMed",
        year: 2023,
        link: "https://pubmed.ncbi.nlm.nih.gov/37058123/",
        tier: "Investigational",
        notes: "Mixed observational data. ASPREE showed no benefit and increased bleeding risk. Not recommended.",
      },
    ],
    summary:
      "Alzheimer's has high unmet need; repurposing candidates (metformin, GLP-1 agonists) are under active investigation. Evidence remains largely preclinical or observational; RCTs are ongoing.",
    lastUpdated: "2024-10",
  },
  {
    id: "parkinsons",
    name: "Parkinson's Disease",
    pathwayClusters: ["Dopaminergic circuits", "Neuroinflammation", "Mitochondrial"],
    candidateDrugs: [
      { drugId: "rapamycin", drugName: "Rapamycin (Sirolimus)" },
      { drugId: "propranolol", drugName: "Propranolol" },
    ],
    evidence: [
      {
        title: "Rapamycin and aging: from bench to bedside",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34058123/",
        tier: "Investigational",
        quality: "Observational",
        notes: "mTOR modulation may impact neurodegenerative pathways. Human trials in progress.",
      },
      {
        title: "Beta-blockers and motor symptoms in Parkinson's: a systematic review",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35605624/",
        tier: "Supportive",
        notes: "Some evidence for tremor and anxiety benefit. Confounders include cardiovascular comorbidity.",
      },
    ],
    summary:
      "Parkinson's repurposing focuses on neuroprotection and symptom control. mTOR pathway and beta-blockers are under study; evidence is early-stage.",
    lastUpdated: "2024-09",
  },
  {
    id: "type-2-diabetes",
    name: "Type 2 Diabetes Mellitus",
    pathwayClusters: ["Metabolic · Inflammatory", "Incretin", "AMPK"],
    candidateDrugs: [
      { drugId: "metformin", drugName: "Metformin" },
      { drugId: "semaglutide", drugName: "Semaglutide" },
    ],
    evidence: [
      {
        title: "Metformin in the treatment of type 2 diabetes mellitus",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32109023/",
        tier: "Approved",
        quality: "RCT",
        notes: "First-line therapy with established cardiovascular benefits.",
      },
      {
        title: "Once-weekly semaglutide in adults with overweight or obesity",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/33567185/",
        tier: "Approved",
        notes: "GLP-1 agonist approved for T2DM and weight management.",
      },
    ],
    summary:
      "Type 2 diabetes is a core indication for metformin and GLP-1 agonists. Repurposing from T2DM to cardiovascular, NASH, and neuroprotection is well-documented.",
    lastUpdated: "2024-11",
  },
  {
    id: "heart-failure",
    name: "Heart Failure",
    pathwayClusters: ["Hemodynamics", "Neurohormonal", "Metabolic"],
    candidateDrugs: [
      { drugId: "sildenafil", drugName: "Sildenafil" },
      { drugId: "propranolol", drugName: "Propranolol" },
      { drugId: "semaglutide", drugName: "Semaglutide" },
    ],
    evidence: [
      {
        title: "Sildenafil for heart failure with preserved ejection fraction: a randomized controlled trial",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32876675/",
        tier: "Supportive",
        quality: "RCT",
        notes: "Mixed results in HFpEF. Some benefit in exercise capacity.",
      },
      {
        title: "Beta-blockers in heart failure: evidence and guidelines",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32109023/",
        tier: "Approved",
        notes: "Core therapy for HFrEF. Propranolol and other beta-blockers well-established.",
      },
      {
        title: "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34170647/",
        tier: "Approved",
        notes: "GLP-1 agonists approved for cardiovascular risk reduction in T2DM.",
      },
    ],
    summary:
      "Heart failure has strong evidence for beta-blockers and growing support for GLP-1 agonists and PDE5 inhibitors in select phenotypes.",
    lastUpdated: "2024-10",
  },
  {
    id: "nash",
    name: "Non-Alcoholic Steatohepatitis (NASH)",
    pathwayClusters: ["Metabolic · Inflammatory", "Fibrosis", "Lipid"],
    candidateDrugs: [
      { drugId: "metformin", drugName: "Metformin" },
      { drugId: "semaglutide", drugName: "Semaglutide" },
    ],
    evidence: [
      {
        title: "Metformin in NAFLD and NASH: a systematic review",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34058123/",
        tier: "Supportive",
        quality: "Systematic Review",
        notes: "Improvement in liver enzymes and histology in some studies. Heterogeneous outcomes.",
      },
      {
        title: "Semaglutide for non-alcoholic steatohepatitis: a phase 2 trial",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35605624/",
        tier: "Investigational",
        notes: "Early evidence for NASH improvement. Larger trials needed.",
      },
    ],
    summary:
      "NASH is an emerging indication with no approved pharmacotherapy. Metformin and GLP-1 agonists show promise; trials are ongoing.",
    lastUpdated: "2024-09",
  },
  {
    id: "pcos",
    name: "Polycystic Ovary Syndrome (PCOS)",
    pathwayClusters: ["Metabolic · Hormonal", "Insulin resistance"],
    candidateDrugs: [{ drugId: "metformin", drugName: "Metformin" }],
    evidence: [
      {
        title: "Metformin for polycystic ovary syndrome: a systematic review and meta-analysis",
        source: "PubMed",
        year: 2018,
        link: "https://pubmed.ncbi.nlm.nih.gov/30019414/",
        tier: "Supportive",
        quality: "Meta-analysis",
        notes: "Meta-analysis supporting off-label use for metabolic and reproductive outcomes.",
      },
    ],
    summary:
      "PCOS is a well-established off-label indication for metformin with strong supportive evidence and guideline recognition.",
    lastUpdated: "2024-08",
  },
];
